drugset / Trial / NCT03215095
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Phase 0
Active not recruiting
11 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collabMedImmune LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good and/or bad, a drug called durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer. Durvalumab is a drug that has been developed to activate the immune system by blocking a protein called programmed death ligand-1 (PD-L1) that can be present on tumor and normal cells, including immune cells.
Timeline
- Start
- 2017-07-10
- Primary completion
- 2023-02-06
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |